By: Indu Bhan
The Supreme Court on Friday restrained Glenmark Pharmaceuticals from the manufacture and institutional sales of branded generic versions of anti-diabetes drug, Sitagliptin, till July 22 even as it allowed it to continue selling existing stocks, asking the trial judge to decide expeditiously on the company’s dispute with US-based Merck, which holds a patent on the drug.
- Glenmark Pharma launches generic version of asthma drug in Denmark
- UCB Inc drags 15 cos,inculding Ranbaxy,Aurobindo,Sun Pharma,Glenmark to court for patent violation
- MSD-Glenmark case replay of Bayer-Cipla patent feud
- HC refuses interim relief to Merck
- Glenmark gets USFDA nod for anti-hypertension drug
- Glenmark settles drug patent dispute with GSK
Meanwhile, drug major Sun Pharmaceutical said it is reviewing a complaint by Meijer Inc alleging anti-trust in connection with Ranbaxy securing market exclusivity for certain products. “Meijer filed complaint, alleging antitrust and RICO Act violations in connection with Ranbaxy securing market exclusivity as part of the FDA’s approval for certain products,” Sun Pharmaceutical said.
With inputs from PTI